Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Triple Negative Breast Cancer Team Project
Team Project

Triple Negative Breast Cancer Team Project

333
Anderson, KarenArizona State University
Anderson, KarenArizona State University
40 biomarkers: 1   NADH dehydrogenase 1a subcomplex, 10      NDUFA10 2   Protein-tyrosine phosphatase, mitochondrial 1      PTPMT1 3   Integrin beta-1      ITGB1 4   Mast/stem cell growth factor receptor      KIT 5   DNA-directed RNA polymerase L, 7.6 kDa      POLR2L 6   Ephrin-A5      EFNA5 7   Regulator of G-protein signaling 5      RGS5 8   TNFR superfamily member 6 (Ab1)      FAS 9   Stomatin-like protein 2      STOML2 10   Signal transducer /activator of transcription 6      STAT6 11   Cysteine-rich protein 2 
Proteomics
Breast and Gynecologic Cancers Research
1

Early diagnosis of triple negative breast cancer would likely have significant impact on overall breast cancer mortality. This proposal is designed to systematically evaluate and compare multiple blood-based biomarkers for triple negative breast cancer. This is a team effort among multiple EDRN members, BDLs, and CEVCs.

The overall study design involves the identification of three distinct types of blood-based biomarkers: 1. Autoantibodies (Anderson/LaBaer) 2. Protein antigens (Li/Lampe; Zangar). 3. miRNA (Huebner/Croce). These biomarkers will be validated in a step-wise fashion using samples provided by the CEVCs and multi-institutional cohorts, with study design and evaluation by the DMCC. Aim 1. Verification of novel biomarkers for TNBC Aim 2. Validate the top biomarkers for TNBC using a diagnostic set of plasma. Aim 3. Determine the sensitivity, specificity, and positive predictive value of the top marker combinations found in aim 2 to distinguish TNBC from benign breast disease, and for the detection of ER+ and Her2+ breast cancer, using the EDRN Reference Set. Aim 4. Develop a phase III validation plan for testing the top biomarkers and biomarker combination for TNBC detection using prediagnostic sera from WHI, ROCA, and PLCO.
We will systematically compare existing TNBC biomarkers that have been identified from multiple laboratories, targeting protein antigens, autoantibodies, and miRNAs. These biomarkers will be validated in a step-wise fashion using samples provided by the CEVCs and multi institutional cohorts, with study design and evaluation by the DMCC. The individual and composite sensitivities and specificities of these biomarkers for the detection of TNBC and non-TNBC breast cancers will be evaluated. These studies will lead to the development of a phase III validation plan for testing the top biomarkers and biomarker combination for TNBC detection using prediagnostic sera from WHI, ROCA, and PLCO.

No datasets are currently associated with this protocol.


Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html